ValuEngine Reduced Rockwell Medical Inc (RMTI) to Sell

ValuEngine Reduced Rockwell Medical Inc (RMTI) to Sell

Rockwell Medical Inc (NASDAQ:RMTI) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

Separately, Zacks Investment Research upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, April 11th.

Shares of Rockwell Medical (NASDAQ:RMTI) traded up 2.83% during trading on Friday, hitting $7.26. 152,189 shares of the stock were exchanged. The firm has a 50 day moving average price of $7.42 and a 200 day moving average price of $6.50. The firm’s market capitalization is $377.93 million. Rockwell Medical has a 52 week low of $3.55 and a 52 week high of $10.58.

Rockwell Medical (NASDAQ:RMTI) last posted its earnings results on Tuesday, May 9th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Rockwell Medical had a negative net margin of 37.98% and a negative return on equity of 33.60%. The business had revenue of $14.60 million for the quarter, compared to the consensus estimate of $12.66 million. During the same period last year, the company earned ($0.10) EPS. The firm’s revenue was up 7.4% compared to the same quarter last year. Analysts forecast that Rockwell Medical will post ($0.39) EPS for the current fiscal year.

In related news, Director Kenneth L. Holt sold 6,000 shares of Rockwell Medical stock in a transaction that occurred on Thursday, March 16th. The shares were sold at an average price of $5.98, for a total transaction of $35,880.00. Following the sale, the director now directly owns 17,430 shares in the company, valued at approximately $104,231.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider David S. Richmond bought 37,210 shares of the business’s stock in a transaction that occurred on Wednesday, March 22nd. The shares were acquired at an average price of $5.84 per share, for a total transaction of $217,306.40. Following the completion of the transaction, the insider now owns 176,412 shares in the company, valued at $1,030,246.08. The disclosure for this purchase can be found here. 15.90% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of RMTI. KCG Holdings Inc. purchased a new position in shares of Rockwell Medical during the first quarter worth about $111,000. Geneva Advisors LLC increased its position in shares of Rockwell Medical by 3.7% in the first quarter. Geneva Advisors LLC now owns 20,970 shares of the company’s stock worth $131,000 after buying an additional 750 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Rockwell Medical by 0.4% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 25,090 shares of the company’s stock worth $165,000 after buying an additional 100 shares during the period. Cutter & CO Brokerage Inc. purchased a new position in shares of Rockwell Medical during the fourth quarter worth about $166,000. Finally, American International Group Inc. increased its position in shares of Rockwell Medical by 7.1% in the first quarter. American International Group Inc. now owns 29,509 shares of the company’s stock worth $185,000 after buying an additional 1,955 shares during the period. Hedge funds and other institutional investors own 21.14% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:RMTI”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

To view ValuEngine’s full report, visit ValuEngine’s official website.

Related posts

Leave a Comment